In Nature Genetics.rst clearly link mutations in the RAD51C genes for breast and ovarian cancerThe discovery 15 years ago that the genes had BRCA1 and BRCA2 conference high risk for breast and ovarian cancer a breakthrough for cancer prognosis and therapy, especially for familial cases. Now the group of Prof. Alfons , can identify, in collaboration with other groups from Germany, Britain and the USA, with another gene that increases susceptibility to breast and ovarian cancer. Their results were published online in Nature Genetics. The identification of such high risk-conferring genes is a prerequisite for the offer women customized screening programs and more individualized therapies.
The new gene than something breast and ovarian cancer identified in familial cases is referred RAD51C. Such as BRCA1 and BRCA2, which. For DNA repair in cells Mutations in the gene can therefore cause either breast or ovarian cancer. In six of 480 progeny with the occurrence of breast and / or ovarian cancer, wurden Mutationen innerhalb des RAD51C Gens gefunden. Rita Schmutzler of the University Hospital of Cologne, one of the other great authors of the article.– The study, data from 2,585 users in the Strongheart trial the conclusion that the outcome bestowed support the expanding amount of data that which indicates that center Print being an important determinant of cardiovascular organ damages, morbidity and mortality than blood pressure blood pressure .. ATCOR Medical , of the development and marketing of the SphygmoCo system of, the central blood printing and vascular stiffness measured noninvasively , announced the publishing a new NIH – financed study* that which the Journal of Hypertension, was to central blood pressure, measured noninvasively having which ATCOR the SphygmoCor system, a main indicator for the development in left ventricular hypertrophy is a brute blood pressure.